6919 — Caliway Biopharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00- TWD94.62bn
- TWD84.96bn
- TWD44.43m
Annual income statement for Caliway Biopharmaceuticals Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.3 | 12.3 | 12.8 | 38.9 | 44.4 |
| Cost of Revenue | |||||
| Gross Profit | 6.67 | 9.23 | 9.61 | 27.5 | 30.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 116 | 243 | 332 | 552 | 762 |
| Operating Profit | -106 | -231 | -320 | -513 | -717 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -98.4 | -224 | -286 | -488 | -589 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -98.5 | -224 | -286 | -488 | -589 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -98.5 | -224 | -286 | -488 | -589 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -98.5 | -224 | -286 | -488 | -589 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.798 | -1.82 | -2.32 | -3.94 | -4.12 |
| Dividends per Share |